Interim data from a GPCR-based optogenetic gene therapy add early human evidence to a mutation-agnostic approach for end-stage retinitis pigmentosa, a disease for which no broadly applicable approved treatment exists. Restore Vision Inc., a Tokyo-based clinical-stage biotechnology company, announced interim results from its Phase I/II trial of RV-001 optogenetic gene therapy, with data from six patients followed for up to 168 days.
The open-label, dose-escalation study enrolled patients with no light perception across two cohorts of three patients each. All participants received a single intravitreal injection of RV-001, an adeno-associated virus vector encoding a chimeric rhodopsin designed to re-sensitize surviving inner retinal neurons to light. The primary endpoint is safety; exploratory assessments include visual acuity by logMAR chart, full-field stimulus testing, and functional vision tasks such as mobility and object recognition. No dose-limiting toxicities or drug-related serious adverse events were reported in either cohort. In the high-dose group, all three patients progressed from no light perception to light perception or better within one month, and one patient achieved chart-based visual acuity measurable by the Berkeley Rudimentary Vision Test. In the low-dose cohort, one of three patients reached light perception at approximately three months. The study remains ongoing, and the company said it plans to expand data collection across broader patient populations. Results were presented at Eyecelerator at ARVO 2026 and the Retinal Therapeutics Innovation Summit on May 1, 2026.
Research context and mechanistic rationale for RV-001 optogenetic gene therapy
Retinitis pigmentosa is caused by mutations in more than 70 genes, all converging on progressive rod and then cone photoreceptor degeneration. By the time patients reach the no-light-perception stage targeted in this trial, photoreceptors are largely absent, but downstream retinal interneurons — including bipolar and ganglion cells — often remain viable. That anatomical reality underpins the optogenetic approach: rather than replacing or correcting the causative mutation, the strategy is to render surviving inner retinal neurons light-sensitive by expressing an exogenous photosensitive protein.
RV-001 delivers a chimeric rhodopsin that combines the cytoplasmic loops of vertebrate rhodopsin, which couple to native G-proteins and activate the endogenous phototransduction cascade, with the transmembrane scaffold of microbial rhodopsin, which confers self-regenerating chromophore properties independent of the retinal pigment epithelium visual cycle. The GPCR gene therapy design is intended to exploit signal amplification inherent to G-protein signaling, potentially enabling light detection under natural ambient conditions without external devices — a practical limitation of earlier channelrhodopsin-based approaches that required high-intensity light stimulation or goggles.
Standard of care and where current approaches fall short
The only approved gene therapy for any form of retinitis pigmentosa remains voretigene neparvovec (Luxturna, Spark Therapeutics), which targets biallelic RPE65 mutations — a subtype affecting roughly 1%–2% of RP patients. For the remaining patient population, no pharmacological or gene-based treatment has received regulatory approval. Supportive measures such as vitamin A supplementation and low-vision aids address neither disease progression nor restoration of function in advanced disease.